Tumors overexpressing the human epidermal growth factor receptor-2 (HER-2 positive) tend to be more aggressive than luminal cancers but by chance are responsive to targeted therapy such as treatment with trastuzumab (Herceptin) aimed at the HER-2 protein. This evidence concerns the gene ERBB2 and cancer.